CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade

Immune checkpoint blockade (ICB) has shown remarkable clinical efficacy in several cancer types. However, only a fraction of patients will respond to ICB. Here, we performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models (CRISPR-GEMMs) in ICB settings, and identi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Discov
Huvudupphovsmän: Wang, Guangchuan, Chow, Ryan D., Zhu, Lvyun, Bai, Zhigang, Ye, Lupeng, Zhang, Feifei, Renauer, Paul A., Dong, Matthew B., Dai, Xiaoyun, Zhang, Xiaoya, Du, Yaying, Cheng, Yujing, Niu, Leilei, Chu, Zhiyuan, Kim, Kristin, Liao, Cun, Clark, Paul, Errami, Youssef, Chen, Sidi
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710536/
https://ncbi.nlm.nih.gov/pubmed/32887696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1448
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk